July 28, 2010
By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D.
Faculty Peer Reviewed
Recent publications have described a potential drug interaction between clopidogrel (Plavix®) and proton pump inhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the…
Read the rest of this entry >>
Posted in Pharmacology
February 24, 2010
John Cruz
Faculty peer reviewed
A number of studies have shown that zolpidem (Ambien), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating behavior among users. Sleep related eating disorder (SRED) is characterized by partial arousals from…
Read the rest of this entry >>
Posted in Pharmacology
November 5, 2009
Kanika Ballani, Pharm.D.
Diana Hubulasvili, Pharm.D.
Developed by Amylin Pharmaceuticals, Exenatide (Byetta®) is an incretin mimetic that is used as an adjunctive therapy with metformin, a sulfonylurea or a thiazolidinedione to improve glycemic control in type 2 diabetic patients. Mechanistically, Exenatide mimics…
Read the rest of this entry >>
Posted in Breaking News, Endocrine, Pharmacology
July 31, 2008
Commentary by Marilena S. Antonopoulos Pharm.D, Pharmacology Section Editor
Until recently, drugs safety alerts (aka “Dear Doctor letters”) were sent out to physicians through traditional U.S. mail, a slow and error-prone process. These alerts can be significantly delayed and may not…
Read the rest of this entry >>
Posted in Pharmacology
July 10, 2008
Commentary by Marilena S. Antonopoulos, PharmD, Pharmacology Editor
On July 8th, the FDA notified the manufacturers of fluoroquinolone antimicrobial drugs that a Boxed Warning in the product labeling and a Medication Guide for patients concerning the increased risk of tendinitis and…
Read the rest of this entry >>
Posted in ID, Pharmacology
May 16, 2008
Commentary by Melissa Freeman, PGY-2
As summertime is just around the corner, many begin to evaluate whether their bodies are ready to expose what has been hidden under those bulky winter clothes. Between busy lives and an innate desire for quick results,…
Read the rest of this entry >>
Posted in Pharmacology
May 1, 2008
Commentary by David Hatcher, MSIII (reviewed by Neil Shapiro, MD Editor-In-Chief, Clinical Correlations)
C.M. is a 68 year-old retired Caucasian male with a past medical history significant for coronary artery disease, hyperlipidemia, HTN, and a 30 pack year history of smoking.…
Read the rest of this entry >>
Posted in Class Act, Pharmacology
December 28, 2007
Is there evidence to support the use of Lantus® (human insulin analog glargine) administered Q12h in Type 1 Diabetes?
Commentary by Kathy Lee, Pharmacy Resident
The goal of diabetes management is to reduce the risk of long-term complications by maintaining near-normal glycemic control,…
Read the rest of this entry >>
Posted in Endocrine, Pharmacology
December 14, 2007
Commentary by Robert Leonard PharmD, Pharmacy Resident New York Harbor Healthcare System
On November 20, 2007 the FDA announced mounting evidence linking varenicline (Chantix®) therapy for smoking cessation with suicidal ideation and erratic and aggressive behavior. The announcement comes in response…
Read the rest of this entry >>
Posted in Pharmacology
November 14, 2007
Commentary by Helen Kourlas PharmD, Pharmacology Section Editor
On October 16th the FDA announced the approval of raltegravir (Isentress®) for the treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents. The use of raltegravir is recommended for patients…
Read the rest of this entry >>
Posted in Pharmacology
October 24, 2007
Commentary by Kathy Lee, Pharm.D. Pharmacy Practice Resident
On October 18 2007, the FDA announced the approval of labeling changes to erectile dysfunction (ED) drugs in the class known as phosphodiesterase type 5 (PDE-5) inhibitors. This includes drugs Cialis®, Levitra®, Viagra®,…
Read the rest of this entry >>
Posted in Pharmacology
October 17, 2007
Commentary by Helen Kourlas, PharmD and John Papadopoulas, PharmD, Pharmacology Section Editors
The sulfonylureas are members of a class of substituted arylsulfonylureas that have been used clinically since the 1950s. These agents are usually divided into two categories or generations. First…
Read the rest of this entry >>
Posted in Pharmacology